9 Meters Biopharma Inc. [NASDAQ: NMTR] price plunged by -10.19 percent to reach at -$0.22. The company report on February 10, 2021 that 9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference.
9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Investor Conference. The conference will be held virtually with all participants joining remotely February 16th – 18th.
The Company’s presentation will be available on demand on the BIO CEO & Investor Conference website and will remain available through March 20, 2021.
A sum of 8699587 shares traded at recent session while its average daily volume was at 10.88M shares. 9 Meters Biopharma Inc. shares reached a high of $2.1419 and dropped to a low of $1.92 until finishing in the latest session at $1.94.
Guru’s Opinion on 9 Meters Biopharma Inc. [NMTR]:
The Average True Range (ATR) for 9 Meters Biopharma Inc. is set at 0.20 The Price to Book ratio for the last quarter was 64.67, with the Price to Cash per share for the same quarter was set at 0.06.
NMTR Stock Performance Analysis:
9 Meters Biopharma Inc. [NMTR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.52. With this latest performance, NMTR shares gained by 46.97% in over the last four-week period, additionally plugging by 247.79% over the last 6 months – not to mention a rise of 156.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NMTR stock in for the last two-week period is set at 64.72, with the RSI for the last a single of trading hit 62.81, and the three-weeks RSI is set at 65.06 for 9 Meters Biopharma Inc. [NMTR]. The present Moving Average for the last 50 days of trading for this stock 1.2364, while it was recorded at 1.9660 for the last single week of trading.
Insight into 9 Meters Biopharma Inc. Fundamentals:
9 Meters Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
NMTR Stock EPS
With the latest financial reports released by the company, 9 Meters Biopharma Inc. posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NMTR.
9 Meters Biopharma Inc. [NMTR] Insider Position Details
There are presently around $118 million, or 22.90% of NMTR stock, in the hands of institutional investors. The top three institutional holders of NMTR stocks are: ORBIMED ADVISORS LLC with ownership of 25,716,755, which is approximately 0% of the company’s market cap and around 0.90% of the total institutional ownership; ADAGE CAPITAL PARTNERS GP, L.L.C., holding 13,000,000 shares of the stock with an approximate value of $25.22 million in NMTR stocks shares; and VANGUARD GROUP INC, currently with $13.95 million in NMTR stock with ownership of nearly 839.418% of the company’s market capitalization.
38 institutional holders increased their position in 9 Meters Biopharma Inc. [NASDAQ:NMTR] by around 32,370,173 shares. Additionally, 12 investors decreased positions by around 1,481,957 shares, while 13 investors held positions by with 26,884,063 shares. The mentioned changes placed institutional holdings at 60,736,193 shares, according to the latest SEC report filing. NMTR stock had 23 new institutional investments in for a total of 22,202,088 shares, while 7 institutional investors sold positions of 386,038 shares during the same period.